|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions affects response to substance increases response to substance decreases uptake increases import increases transport decreases expression affects transport increases export increases expression decreases response to substance |
ISO EXP |
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Daunorubicin results in increased expression of ABCB1 protein]; 4-methyl-N1-(3-phenylpropyl)benzene-1,2-diamine inhibits the reaction [Daunorubicin results in increased expression of ABCB1 mRNA]; 4-methyl-N1-(3-phenylpropyl)benzene-1,2-diamine inhibits the reaction [Daunorubicin results in increased expression of ABCB1 protein]; 5,7-dimethoxyflavone inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]; 5-hydroxyflavone inhibits the reaction [Elacridar inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]]; 5-methoxyflavone inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]; [5-Methoxypsoralen results in decreased activity of ABCB1 protein] which results in decreased export of and results in increased abundance of Daunorubicin; [Carvedilol inhibits the reaction [ABCB1 protein results in increased transport of Daunorubicin]] which results in decreased susceptibility to Daunorubicin; [Daunorubicin co-treated with bromotetrandrine co-treated with Magnetite Nanoparticles] results in decreased expression of ABCB1 mRNA; [Daunorubicin co-treated with bromotetrandrine] results in decreased expression of ABCB1 mRNA; [enasidenib inhibits the reaction [ABCB1 protein results in increased export of Daunorubicin]] which results in increased susceptibility to Daunorubicin; [ginkgolic acid affects the activity of ABCB1 protein] which results in increased abundance of Daunorubicin; [glabridin affects the activity of ABCB1 protein] which results in increased abundance of Daunorubicin; [Glycyrrhetinic Acid affects the activity of ABCB1 protein] which results in increased abundance of Daunorubicin; [Imatinib Mesylate inhibits the reaction [Daunorubicin results in increased expression of ABCB1 protein]] which results in decreased export of Daunorubicin; [matairesinol affects the activity of ABCB1 protein] which results in increased abundance of Daunorubicin; [Methoxsalen results in decreased activity of ABCB1 protein] which results in decreased export of and results in increased abundance of Daunorubicin; [MLN 8237 affects the activity of ABCB1 protein] which affects the export of Daunorubicin; [phyllodulcin affects the activity of ABCB1 protein] which results in increased abundance of Daunorubicin; [sesamin affects the activity of ABCB1 protein] which results in increased abundance of Daunorubicin; [Sodium Azide co-treated with Iodoacetates] inhibits the reaction [ABCB1 protein results in increased export of Daunorubicin]; [venetoclax inhibits the reaction [Daunorubicin results in increased expression of ABCB1 protein]] which results in decreased export of Daunorubicin; [zosuquidar trihydrochloride results in decreased activity of ABCB1 protein] which results in decreased export of Daunorubicin; ABCB1 mutant form promotes the reaction [Daunorubicin results in decreased expression of ABCB1 mRNA]; ABCB1 mutant form promotes the reaction [Daunorubicin results in decreased expression of ABCB1 protein]; ABCB1 mutant form promotes the reaction [Magnetite Nanoparticles results in increased susceptibility to Daunorubicin]; Amiodarone inhibits the reaction [ABCB1 protein results in increased transport of Daunorubicin]; aurapten promotes the reaction [ABCB1 protein results in increased import of Daunorubicin]; azelastine inhibits the reaction [ABCB1 protein results in increased transport of Daunorubicin]; baicalein inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]; baicalein inhibits the reaction [Elacridar inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]]; biochanin A inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]; biochanin A promotes the reaction [Elacridar inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]]; Carvedilol inhibits the reaction [ABCB1 protein results in increased transport of Daunorubicin]; Cyclosporine inhibits the reaction [ABCB1 protein results in increased export of Daunorubicin]; Cyclosporine inhibits the reaction [ABCB1A protein results in increased export of Daunorubicin]; Daunorubicin promotes the reaction [ABCB1 mutant form results in decreased expression of ABCB1 protein]; Daunorubicin promotes the reaction [Magnetite Nanoparticles results in decreased expression of ABCB1 protein]; desethylamiodarone inhibits the reaction [ABCB1 protein results in increased transport of Daunorubicin]; desmethylazelastine inhibits the reaction [ABCB1 protein results in increased transport of Daunorubicin]; dihydromyricetin inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]; Elacridar inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]; enasidenib inhibits the reaction [ABCB1 protein results in decreased susceptibility to Daunorubicin]; enasidenib inhibits the reaction [ABCB1 protein results in increased export of Daunorubicin]; flavone inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]; flavone promotes the reaction [Elacridar inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]]; galangin inhibits the reaction [Elacridar inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]]; glycitein inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]; glycitein promotes the reaction [Elacridar inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]]; Imatinib Mesylate inhibits the reaction [Daunorubicin results in increased expression of ABCB1 protein]; isovitexin inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]; kaempferide inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]; kaempferide inhibits the reaction [Elacridar inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]]; kaempferol inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]; Luteolin inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]; Magnetite Nanoparticles promotes the reaction [ABCB1 mutant form promotes the reaction [Daunorubicin results in decreased expression of ABCB1 mRNA]]; Magnetite Nanoparticles promotes the reaction [ABCB1 mutant form promotes the reaction [Daunorubicin results in decreased expression of ABCB1 protein]]; Magnetite Nanoparticles promotes the reaction [ABCB1 mutant form results in increased susceptibility to Daunorubicin]; Magnetite Nanoparticles promotes the reaction [Daunorubicin promotes the reaction [ABCB1 mutant form results in decreased expression of ABCB1 protein]]; Magnetite Nanoparticles promotes the reaction [Daunorubicin results in decreased expression of ABCB1 mRNA]; Magnetite Nanoparticles promotes the reaction [Daunorubicin results in decreased expression of ABCB1 protein]; Mitotane inhibits the reaction [ABCB1 protein results in increased export of Daunorubicin]; naringenin inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]; naringenin inhibits the reaction [Elacridar inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]]; nobiletin promotes the reaction [ABCB1 protein results in increased import of Daunorubicin]; puerarin inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]; Quercetin inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]; schaftoside inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]; Sesquiterpenes analog inhibits the reaction [ABCB1 protein results in decreased susceptibility to Daunorubicin]; Silybin inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]; Silybin promotes the reaction [Elacridar inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]]; tangeretin inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]; valspodar inhibits the reaction [ABCB1 protein results in increased export of Daunorubicin]; venetoclax inhibits the reaction [Daunorubicin results in increased expression of ABCB1 protein]; Verapamil inhibits the reaction [[5-Methoxypsoralen results in decreased activity of ABCB1 protein] which results in decreased export of and results in increased abundance of Daunorubicin]; Verapamil inhibits the reaction [[Methoxsalen results in decreased activity of ABCB1 protein] which results in decreased export of and results in increased abundance of Daunorubicin]; Verapamil inhibits the reaction [ABCB1 protein results in increased transport of Daunorubicin]; zosuquidar trihydrochloride inhibits the reaction [ABCB1 protein results in increased export of Daunorubicin] ABCB1 affects the susceptibility to Daunorubicin; ABCB1 protein affects the susceptibility to Daunorubicin Daunorubicin results in decreased expression of ABCB1 mRNA; Daunorubicin results in decreased expression of ABCB1 protein ABCB1 protein affects the transport of Daunorubicin ABCB1 protein results in increased export of Daunorubicin; ABCB1A protein results in increased export of Daunorubicin Daunorubicin inhibits the reaction [ABCB1 results in increased transport of estradiol-17 beta-glucuronide] ABCB1A affects the susceptibility to Daunorubicin Daunorubicin results in increased expression of ABCB1 mRNA; Daunorubicin results in increased expression of ABCB1 protein |
CTD |
PMID:9794924 PMID:9815696 PMID:10617675 PMID:11231118 PMID:12107549 PMID:12174371 PMID:12526924 PMID:12642476 PMID:12708479 PMID:15466210 PMID:16636798 PMID:18204840 PMID:18955043 PMID:20957165 PMID:22114476 PMID:24954033 PMID:29079042 PMID:34217736 PMID:34896433 PMID:34963561 PMID:35972551 More...
|
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcb8 |
ATP binding cassette subfamily B member 8 |
decreases expression |
EXP |
Daunorubicin results in decreased expression of ABCB8 mRNA |
CTD |
PMID:27090888 |
|
NCBI chr 4:10,766,206...10,783,598
Ensembl chr 4:10,768,281...10,783,589
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
affects export affects response to substance multiple interactions decreases response to substance decreases uptake increases secretion increases export |
ISO |
ABCC1 protein affects the export of Daunorubicin ABCC1 affects the susceptibility to Daunorubicin; ABCC1 protein affects the susceptibility to Daunorubicin [enasidenib inhibits the reaction [ABCC1 protein results in increased export of Daunorubicin]] which results in increased susceptibility to Daunorubicin; [MLN 8237 results in decreased activity of ABCC1 protein] which results in decreased export of Daunorubicin; [MLN 8237 results in decreased activity of ABCC1 protein] which results in increased susceptibility to Daunorubicin; [verlukast results in decreased activity of ABCC1 protein] which results in decreased export of Daunorubicin; Benzbromarone inhibits the reaction [ABCC1 protein results in increased secretion of Daunorubicin]; Camptothecin inhibits the reaction [ABCC1 results in decreased susceptibility to Daunorubicin]; enasidenib inhibits the reaction [ABCC1 protein results in decreased susceptibility to Daunorubicin]; enasidenib inhibits the reaction [ABCC1 protein results in increased export of Daunorubicin]; Folic Acid deficiency inhibits the reaction [ABCC1 protein results in increased secretion of Daunorubicin]; homocamptothecin inhibits the reaction [ABCC1 protein results in increased secretion of Daunorubicin]; PAK 104P inhibits the reaction [ABCC1 protein affects the export of Daunorubicin]; Verapamil inhibits the reaction [ABCC1 protein affects the export of Daunorubicin]; verlukast inhibits the reaction [ABCC1 protein results in increased export of Daunorubicin] ABCC1 protein results in decreased susceptibility to Daunorubicin; ABCC1 results in decreased susceptibility to Daunorubicin Daunorubicin promotes the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; Glucose inhibits the reaction [Sodium Azide inhibits the reaction [ABCC1 protein results in decreased uptake of Daunorubicin]]; Sodium Azide inhibits the reaction [ABCC1 protein results in decreased uptake of Daunorubicin]; Verapamil inhibits the reaction [ABCC1 protein results in decreased uptake of Daunorubicin] |
CTD |
PMID:7954421 PMID:8968083 PMID:9096673 PMID:9334814 PMID:10856430 PMID:12088114 PMID:12115804 PMID:12174371 PMID:12657726 PMID:15041471 PMID:15498506 PMID:18451141 PMID:34896433 PMID:35972551 More...
|
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
affects response to substance multiple interactions |
ISO |
ABCC2 affects the susceptibility to Daunorubicin [5-methoxypsoralen results in decreased activity of ABCC2 protein] which results in decreased export of and results in increased abundance of Daunorubicin; [Methoxsalen results in decreased activity of ABCC2 protein] which results in decreased export of and results in increased abundance of Daunorubicin; Indomethacin inhibits the reaction [[5-methoxypsoralen results in decreased activity of ABCC2 protein] which results in decreased export of and results in increased abundance of Daunorubicin]; Indomethacin inhibits the reaction [[Methoxsalen results in decreased activity of ABCC2 protein] which results in decreased export of and results in increased abundance of Daunorubicin] |
CTD |
PMID:18451141 PMID:29079042 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions increases expression decreases response to substance increases export |
ISO |
3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester inhibits the reaction [ABCG2 protein results in increased export of Daunorubicin]; [enasidenib inhibits the reaction [ABCG2 protein results in increased export of Daunorubicin]] which results in increased susceptibility to Daunorubicin; Dactinomycin inhibits the reaction [Daunorubicin results in increased expression of ABCG2 mRNA]; enasidenib inhibits the reaction [ABCG2 protein results in decreased susceptibility to Daunorubicin]; enasidenib inhibits the reaction [ABCG2 protein results in increased export of Daunorubicin] |
CTD |
PMID:20019844 PMID:35972551 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Abl1 |
ABL proto-oncogene 1, non-receptor tyrosine kinase |
decreases response to substance |
ISO |
ABL1 results in decreased susceptibility to Daunorubicin |
CTD |
PMID:12410571 |
|
NCBI chr 3:14,979,853...15,083,065
Ensembl chr 3:14,979,853...15,083,065
|
|
G |
Acta1 |
actin, alpha 1, skeletal muscle |
decreases expression |
ISO |
Daunorubicin results in decreased expression of ACTA1 mRNA |
CTD |
PMID:26537877 PMID:28940058 |
|
NCBI chr19:51,883,713...51,886,725
Ensembl chr19:51,883,715...51,886,742
|
|
G |
Agrn |
agrin |
increases expression |
ISO |
Daunorubicin results in increased expression of AGRN mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 5:166,749,306...166,782,212
Ensembl chr 5:166,749,310...166,786,003
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
multiple interactions increases expression |
EXP |
telmisartan inhibits the reaction [Daunorubicin results in increased expression of AGTR1A protein] |
CTD |
PMID:20888384 |
|
NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946
|
|
G |
Akr1a1 |
aldo-keto reductase family 1 member A1 |
increases reduction increases metabolic processing multiple interactions affects metabolic processing |
ISO |
AKR1A1 protein results in increased reduction of Daunorubicin AKR1A1 results in increased metabolism of Daunorubicin [AKR1A1 results in increased metabolism of Daunorubicin] which results in increased chemical synthesis of daunorubicinol AKR1A1 SNP affects the metabolism of Daunorubicin |
CTD |
PMID:18276838 PMID:18322072 |
|
NCBI chr 5:130,092,945...130,130,277
Ensembl chr 5:130,092,732...130,113,674
|
|
G |
Akr1b1 |
aldo-keto reductase family 1 member B1 |
increases reduction |
ISO |
AKR1B1 protein results in increased reduction of Daunorubicin |
CTD |
PMID:10510318 |
|
NCBI chr 4:62,932,033...62,946,126
Ensembl chr 4:62,932,031...62,946,157
|
|
G |
Akr1b10 |
aldo-keto reductase family 1 member B10 |
decreases response to substance multiple interactions increases reduction |
ISO |
AKR1B10 protein results in decreased susceptibility to Daunorubicin [AKR1B10 protein results in increased reduction of Daunorubicin] which results in increased chemical synthesis of daunorubicinol; ciprofibrate inhibits the reaction [AKR1B10 protein results in increased reduction of Daunorubicin]; ethyl 1-benzyl-3-hydroxy-2(5H)-oxopyrrole-4-carboxylate inhibits the reaction [AKR1B10 protein results in increased reduction of Daunorubicin]; Fenofibrate inhibits the reaction [AKR1B10 protein results in increased reduction of Daunorubicin]; fenofibric acid inhibits the reaction [AKR1B10 protein results in increased reduction of Daunorubicin]; pirinixic acid inhibits the reaction [AKR1B10 protein results in increased reduction of Daunorubicin]; sorbinil inhibits the reaction [AKR1B10 protein results in increased reduction of Daunorubicin]; zopolrestat inhibits the reaction [AKR1B10 protein results in increased reduction of Daunorubicin] |
CTD |
PMID:19028477 |
|
NCBI chr 4:63,038,459...63,060,336
Ensembl chr 4:63,040,169...63,053,852
|
|
G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
increases metabolic processing multiple interactions decreases response to substance increases reduction |
ISO |
AKR1C3 protein results in increased metabolism of Daunorubicin; AKR1C3 results in increased metabolism of Daunorubicin [AKR1C3 protein results in increased metabolism of Daunorubicin] which results in increased abundance of daunorubicinol; [AKR1C3 protein results in increased reduction of Daunorubicin] which results in increased abundance of daunorubicinol; [Tretinoin results in decreased activity of AKR1C3 protein] which results in increased susceptibility to Daunorubicin; dinaciclib inhibits the reaction [AKR1C3 protein results in decreased susceptibility to Daunorubicin]; enasidenib inhibits the reaction [[AKR1C3 protein results in increased reduction of Daunorubicin] which results in increased abundance of daunorubicinol]; enasidenib inhibits the reaction [AKR1C3 protein results in decreased susceptibility to Daunorubicin]; enasidenib inhibits the reaction [AKR1C3 protein results in increased reduction of Daunorubicin]; midostaurin inhibits the reaction [AKR1C3 protein results in decreased susceptibility to Daunorubicin]; midostaurin inhibits the reaction [AKR1C3 protein results in increased metabolism of Daunorubicin]; NVP-BKM120 inhibits the reaction [AKR1C3 protein results in increased reduction of and results in decreased susceptibility to Daunorubicin]; Tretinoin inhibits the reaction [[AKR1C3 protein results in increased metabolism of Daunorubicin] which results in increased abundance of daunorubicinol]; Tretinoin inhibits the reaction [AKR1C3 protein results in increased metabolism of Daunorubicin] |
CTD |
PMID:20837989 PMID:29992508 PMID:30703376 PMID:32588086 PMID:33025066 PMID:35972551 More...
|
|
NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases response to substance multiple interactions decreases phosphorylation |
ISO |
AKT1 protein results in decreased susceptibility to Daunorubicin [4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole co-treated with AKT1 protein] inhibits the reaction [Daunorubicin results in decreased expression of MCL1 mRNA]; [4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole co-treated with AKT1 protein] inhibits the reaction [Daunorubicin results in decreased expression of MCL1 protein]; Acetylcysteine inhibits the reaction [Daunorubicin results in decreased phosphorylation of AKT1 protein]; AKT1 protein inhibits the reaction [Daunorubicin results in decreased expression of MCL1 mRNA]; AKT1 protein inhibits the reaction [Daunorubicin results in decreased expression of MCL1 protein]; AKT1 protein inhibits the reaction [Daunorubicin results in decreased expression of SP1 protein]; AKT1 protein inhibits the reaction [Daunorubicin results in decreased phosphorylation of MAPK1 protein]; AKT1 protein inhibits the reaction [Daunorubicin results in decreased phosphorylation of MAPK3 protein] |
CTD |
PMID:22252735 PMID:34963561 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Angpt1 |
angiopoietin 1 |
decreases expression |
EXP |
Daunorubicin results in decreased expression of ANGPT1 mRNA; Daunorubicin results in decreased expression of ANGPT1 protein |
CTD |
PMID:16626513 |
|
NCBI chr 7:73,528,345...73,783,953
Ensembl chr 7:73,531,486...73,784,067
|
|
G |
Angpt2 |
angiopoietin 2 |
increases expression |
EXP |
Daunorubicin results in increased expression of ANGPT2 mRNA; Daunorubicin results in increased expression of ANGPT2 protein |
CTD |
PMID:16626513 |
|
NCBI chr16:71,088,364...71,138,805
Ensembl chr16:71,088,364...71,138,804
|
|
G |
Ank2 |
ankyrin 2 |
decreases expression |
ISO |
Daunorubicin results in decreased expression of ANK2 mRNA |
CTD |
PMID:26537877 PMID:28940058 |
|
NCBI chr 2:215,378,028...215,954,015
Ensembl chr 2:215,379,680...215,862,923
|
|
G |
Ankrd1 |
ankyrin repeat domain 1 |
decreases expression |
EXP |
Daunorubicin results in decreased expression of ANKRD1 mRNA |
CTD |
PMID:9278441 |
|
NCBI chr 1:233,815,851...233,834,891
Ensembl chr 1:233,815,851...233,834,919
|
|
G |
Ano3 |
anoctamin 3 |
affects response to substance |
ISO |
ANO3 affects the susceptibility to Daunorubicin |
CTD |
PMID:17545624 |
|
NCBI chr 3:97,235,671...97,550,090
Ensembl chr 3:97,238,354...97,550,154
|
|
G |
Anxa2 |
annexin A2 |
decreases expression |
ISO |
Daunorubicin results in decreased expression of ANXA2 mRNA; Daunorubicin results in decreased expression of ANXA2 protein |
CTD |
PMID:21223737 |
|
NCBI chr 8:70,105,268...70,141,663
Ensembl chr 8:70,105,253...70,141,658
|
|
G |
Anxa4 |
annexin A4 |
increases expression |
ISO |
Daunorubicin results in increased expression of ANXA4 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 4:119,184,378...119,241,183
Ensembl chr 4:119,184,374...119,241,161
|
|
G |
Apex1 |
apurinic/apyrimidinic endodeoxyribonuclease 1 |
multiple interactions |
ISO |
APEX1 protein results in increased reduction of and results in increased susceptibility to Daunorubicin |
CTD |
PMID:10190555 |
|
NCBI chr15:24,144,595...24,146,785
Ensembl chr15:24,144,362...24,146,785
|
|
G |
Apob |
apolipoprotein B |
increases expression |
EXP |
Daunorubicin results in increased expression of APOB protein |
CTD |
PMID:7637207 |
|
NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497
|
|
G |
Apoc3 |
apolipoprotein C3 |
increases expression |
EXP |
Daunorubicin results in increased expression of APOC3 protein |
CTD |
PMID:7637207 |
|
NCBI chr 8:46,531,478...46,533,658
Ensembl chr 8:46,531,478...46,533,583
|
|
G |
Ar |
androgen receptor |
increases activity decreases activity |
ISO |
Daunorubicin results in increased activity of AR protein Daunorubicin results in decreased activity of AR protein |
CTD |
PMID:25257666 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Atm |
ATM serine/threonine kinase |
increases expression |
ISO |
Daunorubicin results in increased expression of ATM mRNA |
CTD |
PMID:12656675 |
|
NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437
|
|
G |
Atp1a2 |
ATPase Na+/K+ transporting subunit alpha 2 |
decreases expression |
ISO |
Daunorubicin results in decreased expression of ATP1A2 mRNA |
CTD |
PMID:26537877 PMID:28940058 |
|
NCBI chr13:84,729,597...84,754,544
Ensembl chr13:84,729,601...84,754,544
|
|
G |
Atxn1 |
ataxin 1 |
decreases expression |
EXP |
Daunorubicin results in decreased expression of ATXN1 mRNA |
CTD |
PMID:27090888 |
|
NCBI chr17:18,737,491...19,142,360
Ensembl chr17:18,737,533...19,142,360
|
|
G |
Aurka |
aurora kinase A |
decreases expression |
ISO |
Daunorubicin results in decreased expression of AURKA protein |
CTD |
PMID:23872705 |
|
NCBI chr 3:161,128,309...161,144,524
Ensembl chr 3:161,128,313...161,144,390
|
|
G |
Bard1 |
BRCA1 associated RING domain 1 |
affects expression |
ISO |
Daunorubicin affects the expression of BARD1 mRNA |
CTD |
PMID:12656675 |
|
NCBI chr 9:72,616,070...72,694,553
Ensembl chr 9:72,623,155...72,694,265
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
ISO |
[bromotetrandrine co-treated with Daunorubicin] results in increased expression of BAX mRNA; [bromotetrandrine co-treated with Daunorubicin] results in increased expression of BAX protein; [Daunorubicin co-treated with bromotetrandrine co-treated with Magnetite Nanoparticles] results in increased expression of BAX mRNA; [Daunorubicin co-treated with bromotetrandrine co-treated with Magnetite Nanoparticles] results in increased expression of BAX protein; [Daunorubicin co-treated with bromotetrandrine] results in increased expression of BAX mRNA; [Daunorubicin co-treated with bromotetrandrine] results in increased expression of BAX protein; [Daunorubicin co-treated with Magnetite Nanoparticles] results in increased expression of BAX mRNA; [Magnetite Nanoparticles co-treated with Daunorubicin] promotes the reaction [bromotetrandrine results in increased expression of BAX protein]; [Magnetite Nanoparticles co-treated with Daunorubicin] results in increased expression of BAX mRNA; [Magnetite Nanoparticles co-treated with Daunorubicin] results in increased expression of BAX protein; bromotetrandrine promotes the reaction [[ferric oxide co-treated with ferrous oxide co-treated with Daunorubicin] results in increased expression of BAX protein]; bromotetrandrine promotes the reaction [[Magnetite Nanoparticles co-treated with Daunorubicin] results in increased expression of BAX mRNA]; Magnetite Nanoparticles promotes the reaction [[bromotetrandrine co-treated with Daunorubicin] results in increased expression of BAX mRNA] Daunorubicin results in increased expression of BAX mRNA |
CTD |
PMID:19421372 PMID:19918366 PMID:21720514 PMID:26537877 PMID:28940058 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases response to substance decreases expression affects expression |
ISO |
[Bortezomib co-treated with Daunorubicin] results in decreased expression of BCL2 mRNA; [bromotetrandrine co-treated with Daunorubicin] results in decreased expression of BCL2 protein; [Daunorubicin co-treated with bromotetrandrine co-treated with Magnetite Nanoparticles] results in decreased expression of BCL2 mRNA; [Daunorubicin co-treated with bromotetrandrine co-treated with Magnetite Nanoparticles] results in decreased expression of BCL2 protein; [Daunorubicin co-treated with bromotetrandrine] results in decreased expression of BCL2 mRNA; [Daunorubicin co-treated with bromotetrandrine] results in decreased expression of BCL2 protein; [Daunorubicin co-treated with Magnetite Nanoparticles] results in decreased expression of BCL2 mRNA; [Magnetite Nanoparticles co-treated with Daunorubicin] promotes the reaction [bromotetrandrine results in decreased expression of BCL2 protein]; [Magnetite Nanoparticles co-treated with Daunorubicin] results in decreased expression of BCL2 protein; bromotetrandrine promotes the reaction [[Magnetite Nanoparticles co-treated with Daunorubicin] results in decreased expression of BCL2 protein]; bromotetrandrine promotes the reaction [Daunorubicin results in decreased expression of BCL2 mRNA]; bromotetrandrine promotes the reaction [Magnetite Nanoparticles promotes the reaction [Daunorubicin results in decreased expression of BCL2 mRNA]]; Magnetite Nanoparticles promotes the reaction [bromotetrandrine promotes the reaction [Daunorubicin results in decreased expression of BCL2 mRNA]]; Magnetite Nanoparticles promotes the reaction [Daunorubicin results in decreased expression of BCL2 mRNA] BCL2 results in decreased susceptibility to Daunorubicin Daunorubicin affects the expression of BCL2 mRNA |
CTD |
PMID:19421372 PMID:19918366 PMID:21302442 PMID:21595920 PMID:21720514 PMID:27780733 More...
|
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bid |
BH3 interacting domain death agonist |
multiple interactions |
ISO |
[Daunorubicin co-treated with TNFSF10 protein] results in increased expression of BID protein |
CTD |
PMID:12780785 |
|
NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions affects expression increases expression |
ISO |
[bromotetrandrine co-treated with Daunorubicin] results in decreased expression of BIRC5 mRNA; [bromotetrandrine co-treated with Daunorubicin] results in decreased expression of BIRC5 protein; [Daunorubicin co-treated with bromotetrandrine co-treated with Magnetite Nanoparticles] results in decreased expression of BIRC5 mRNA; [Daunorubicin co-treated with bromotetrandrine co-treated with Magnetite Nanoparticles] results in decreased expression of BIRC5 protein; [Daunorubicin co-treated with bromotetrandrine] results in decreased expression of BIRC5 mRNA; [Daunorubicin co-treated with bromotetrandrine] results in decreased expression of BIRC5 protein Daunorubicin affects the expression of BIRC5 mRNA Daunorubicin results in increased expression of BIRC5 mRNA; Daunorubicin results in increased expression of BIRC5 protein |
CTD |
PMID:16638212 PMID:21362215 PMID:21720514 PMID:27780733 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Btrc |
beta-transducin repeat containing E3 ubiquitin protein ligase |
multiple interactions increases expression |
ISO |
BTRC protein inhibits the reaction [Daunorubicin results in decreased expression of SP1 protein]; BTRC protein modified form inhibits the reaction [Daunorubicin results in decreased expression of SP1 protein]; Daunorubicin results in increased expression of and results in increased stability of BTRC mRNA; MAP2K1 protein inhibits the reaction [Daunorubicin results in increased expression of BTRC mRNA]; MAP2K1 protein inhibits the reaction [Daunorubicin results in increased expression of BTRC protein] Daunorubicin results in increased expression of BTRC mRNA; Daunorubicin results in increased expression of BTRC protein |
CTD |
PMID:34963561 |
|
NCBI chr 1:244,210,299...244,380,126
Ensembl chr 1:244,210,314...244,376,721
|
|
G |
Cab39 |
calcium binding protein 39 |
decreases expression |
ISO |
Daunorubicin results in decreased expression of CAB39 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 9:86,463,008...86,524,545
Ensembl chr 9:86,463,095...86,524,544
|
|
G |
Cacna1g |
calcium voltage-gated channel subunit alpha1 G |
decreases expression |
ISO |
Daunorubicin results in decreased expression of CACNA1G mRNA |
CTD |
PMID:26537877 PMID:28940058 |
|
NCBI chr10:79,354,998...79,422,960
Ensembl chr10:79,355,008...79,422,752
|
|
G |
Cacna1s |
calcium voltage-gated channel subunit alpha1 S |
affects response to substance |
ISO |
CACNA1S affects the susceptibility to Daunorubicin |
CTD |
PMID:17545624 |
|
NCBI chr13:47,493,949...47,564,194
Ensembl chr13:47,493,949...47,564,318
|
|
G |
Cacna2d2 |
calcium voltage-gated channel auxiliary subunit alpha2delta 2 |
decreases expression |
ISO |
Daunorubicin results in decreased expression of CACNA2D2 mRNA |
CTD |
PMID:26537877 PMID:28940058 |
|
NCBI chr 8:108,072,208...108,203,516
Ensembl chr 8:108,072,454...108,203,173
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity affects expression increases cleavage |
ISO |
[bromotetrandrine co-treated with Daunorubicin] results in increased expression of CASP3 mRNA; [bromotetrandrine co-treated with Daunorubicin] results in increased expression of CASP3 protein; [Daunorubicin co-treated with bromotetrandrine co-treated with Magnetite Nanoparticles] results in increased expression of CASP3 mRNA; [Daunorubicin co-treated with bromotetrandrine co-treated with Magnetite Nanoparticles] results in increased expression of CASP3 protein; [Daunorubicin co-treated with bromotetrandrine] results in increased expression of CASP3 mRNA; [Daunorubicin co-treated with bromotetrandrine] results in increased expression of CASP3 protein; [Daunorubicin co-treated with Magnetite Nanoparticles] results in increased expression of CASP3 mRNA; [Daunorubicin co-treated with TNFSF10 protein] results in increased activity of CASP3 protein; [Magnetite Nanoparticles co-treated with Daunorubicin] promotes the reaction [bromotetrandrine results in increased expression of CASP3 protein]; [Magnetite Nanoparticles co-treated with Daunorubicin] results in increased expression of CASP3 mRNA; [Magnetite Nanoparticles co-treated with Daunorubicin] results in increased expression of CASP3 protein; bromotetrandrine promotes the reaction [[ferric oxide co-treated with ferrous oxide co-treated with Daunorubicin] results in increased expression of CASP3 protein]; bromotetrandrine promotes the reaction [[Magnetite Nanoparticles co-treated with Daunorubicin] results in increased expression of CASP3 mRNA]; Magnetite Nanoparticles promotes the reaction [[bromotetrandrine co-treated with Daunorubicin] results in increased expression of CASP3 mRNA] Daunorubicin results in increased activity of CASP3 protein Daunorubicin affects the expression of CASP3 mRNA Daunorubicin results in increased cleavage of CASP3 protein |
CTD |
PMID:10766178 PMID:12780785 PMID:17699722 PMID:17965967 PMID:19421372 PMID:19698806 PMID:19918366 PMID:21720514 PMID:25003661 PMID:27780733 PMID:34963561 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
[Daunorubicin co-treated with TNFSF10 protein] results in increased activity of CASP8 protein |
CTD |
PMID:12780785 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
affects expression increases cleavage |
ISO |
Daunorubicin affects the expression of CASP9 mRNA Daunorubicin results in increased cleavage of CASP9 protein |
CTD |
PMID:27780733 PMID:34963561 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
affects response to substance |
ISO |
CAT protein affects the susceptibility to Daunorubicin |
CTD |
PMID:11178967 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cavin4 |
caveolae associated protein 4 |
decreases expression |
ISO |
Daunorubicin results in decreased expression of CAVIN4 mRNA |
CTD |
PMID:26537877 PMID:28940058 |
|
NCBI chr 5:62,996,975...63,004,819
Ensembl chr 5:62,996,865...63,007,678
|
|
G |
Cbr1 |
carbonyl reductase 1 |
increases metabolic processing decreases metabolic processing increases reduction multiple interactions |
ISO |
CBR1 protein results in increased metabolism of Daunorubicin; CBR1 results in increased metabolism of Daunorubicin CBR1 gene SNP results in decreased metabolism of Daunorubicin CBR1 protein results in increased reduction of Daunorubicin 8-prenylnaringenin inhibits the reaction [CBR1 protein results in increased metabolism of Daunorubicin]; [[Curcumin binds to and results in decreased activity of CBR1 protein] which results in decreased reduction of Daunorubicin] which results in decreased chemical synthesis of daunorubicinol; [CBR1 protein results in increased reduction of Daunorubicin] which results in increased chemical synthesis of daunorubicinol; [CBR1 results in increased metabolism of Daunorubicin] which results in increased chemical synthesis of daunorubicinol; [Curcumin binds to and results in decreased activity of CBR1 protein] which results in decreased reduction of Daunorubicin; [S-Nitrosoglutathione binds to CBR1 protein] inhibits the reaction [CBR1 protein results in increased metabolism of Daunorubicin]; isoxanthohumol inhibits the reaction [CBR1 protein results in increased metabolism of Daunorubicin]; xanthohumol inhibits the reaction [CBR1 protein results in increased metabolism of Daunorubicin] |
CTD |
PMID:18579125 PMID:19204081 PMID:20670211 PMID:23295225 PMID:25541467 PMID:30849340 More...
|
|
NCBI chr11:32,860,618...32,862,981
Ensembl chr11:32,908,950...32,911,393 Ensembl chr11:32,908,950...32,911,393
|
|
G |
Cbr3 |
carbonyl reductase 3 |
affects response to substance affects metabolic processing |
ISO |
CBR3 gene SNP affects the susceptibility to Daunorubicin CBR3 protein affects the metabolism of Daunorubicin; CBR3 protein alternative form affects the metabolism of Daunorubicin |
CTD |
PMID:20007405 |
|
NCBI chr11:33,008,615...33,016,877
Ensembl chr11:33,008,615...33,016,875
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
decreases expression |
ISO |
Daunorubicin results in decreased expression of CCL2 protein |
CTD |
PMID:20116850 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl4 |
C-C motif chemokine ligand 4 |
decreases expression |
ISO |
Daunorubicin results in decreased expression of CCL4 protein |
CTD |
PMID:20116850 |
|
NCBI chr10:68,466,469...68,467,941
Ensembl chr10:68,452,052...68,468,231
|
|
G |
Ccnd3 |
cyclin D3 |
increases expression |
ISO |
Daunorubicin results in increased expression of CCND3 mRNA |
CTD |
PMID:12656675 |
|
NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371
|
|
G |
Ccne1 |
cyclin E1 |
affects expression |
ISO |
Daunorubicin affects the expression of CCNE1 mRNA |
CTD |
PMID:12656675 |
|
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
|
|
G |
Ccng2 |
cyclin G2 |
increases expression |
ISO |
Daunorubicin results in increased expression of CCNG2 mRNA |
CTD |
PMID:18754885 |
|
NCBI chr14:14,804,321...14,812,819
Ensembl chr14:14,804,322...14,812,830
|
|
G |
Cd34 |
CD34 molecule |
decreases expression |
EXP |
Daunorubicin results in decreased expression of CD34 mRNA |
CTD |
PMID:27090888 |
|
NCBI chr13:106,480,074...106,499,462
Ensembl chr13:106,480,043...106,499,832
|
|
G |
Cdc25a |
cell division cycle 25A |
increases expression |
ISO |
Daunorubicin results in increased expression of CDC25A mRNA |
CTD |
PMID:12656675 |
|
NCBI chr 8:109,864,356...109,882,734
Ensembl chr 8:109,864,478...109,882,701
|
|
G |
Cdh13 |
cadherin 13 |
affects response to substance |
ISO |
CDH13 affects the susceptibility to Daunorubicin |
CTD |
PMID:17545624 |
|
NCBI chr19:46,349,562...47,387,462
Ensembl chr19:46,349,430...47,387,459
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO |
Daunorubicin results in increased expression of CDKN1A; Daunorubicin results in increased expression of CDKN1A mRNA; Daunorubicin results in increased expression of CDKN1A protein |
CTD |
PMID:12112851 PMID:12656675 PMID:23872705 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
multiple interactions affects expression |
EXP |
fasudil affects the reaction [Daunorubicin affects the expression of CDKN1B mRNA] |
CTD |
PMID:20037814 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
affects expression |
ISO |
Daunorubicin affects the expression of CDKN2A mRNA |
CTD |
PMID:12656675 |
|
NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
|
|
G |
Cdkn2b |
cyclin-dependent kinase inhibitor 2B |
increases expression |
ISO |
Daunorubicin results in increased expression of CDKN2B mRNA |
CTD |
PMID:12656675 |
|
NCBI chr 5:104,009,839...104,019,082
Ensembl chr 5:104,010,680...104,019,050
|
|
G |
Ceacam1 |
CEA cell adhesion molecule 1 |
increases expression |
ISO |
Daunorubicin results in increased expression of CEACAM1 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 1:81,043,595...81,060,050
Ensembl chr 1:81,043,595...81,059,992
|
|
G |
Cebpz |
CCAAT/enhancer binding protein zeta |
decreases expression |
ISO |
Daunorubicin results in decreased expression of CEBPZ mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 6:16,119,871...16,137,600
Ensembl chr 6:16,119,872...16,137,600
|
|
G |
Ckm |
creatine kinase, M-type |
decreases expression |
ISO |
Daunorubicin results in decreased expression of CKM mRNA |
CTD |
PMID:26537877 PMID:28940058 |
|
NCBI chr 1:79,061,390...79,071,721
Ensembl chr 1:79,061,456...79,071,720
|
|
G |
Clk2 |
CDC-like kinase 2 |
increases expression |
ISO |
Daunorubicin results in increased expression of CLK2 mRNA |
CTD |
PMID:12656675 |
|
NCBI chr 2:174,570,614...174,582,645
Ensembl chr 2:174,570,653...174,588,985
|
|
G |
Clybl |
citramalyl-CoA lyase |
affects response to substance |
ISO |
CLYBL affects the susceptibility to Daunorubicin |
CTD |
PMID:17545624 |
|
NCBI chr15:99,283,644...99,505,697
Ensembl chr15:99,283,650...99,505,695
|
|
G |
Cmc2 |
C-x(9)-C motif containing 2 |
affects response to substance |
ISO |
CMC2 affects the susceptibility to Daunorubicin |
CTD |
PMID:17545624 |
|
NCBI chr19:44,943,283...44,997,408
Ensembl chr19:44,943,285...44,971,983
|
|
G |
Cmip |
c-Maf-inducing protein |
affects response to substance |
ISO |
CMIP affects the susceptibility to Daunorubicin |
CTD |
PMID:17545624 |
|
NCBI chr19:45,304,597...45,510,653
Ensembl chr19:45,304,031...45,508,709
|
|
G |
Corin |
corin, serine peptidase |
decreases expression |
ISO |
Daunorubicin results in decreased expression of CORIN mRNA |
CTD |
PMID:26537877 PMID:28940058 |
|
NCBI chr14:35,680,601...35,910,703
Ensembl chr14:35,681,304...35,909,503
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
decreases phosphorylation multiple interactions |
ISO |
Daunorubicin results in decreased phosphorylation of CREB1 protein 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Daunorubicin results in decreased phosphorylation of CREB1 protein]; Okadaic Acid inhibits the reaction [Daunorubicin results in decreased phosphorylation of CREB1 protein] |
CTD |
PMID:34963561 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Cwc27 |
CWC27 spliceosome associated cyclophilin |
affects response to substance |
ISO |
CWC27 affects the susceptibility to Daunorubicin |
CTD |
PMID:17545624 |
|
NCBI chr 2:35,764,674...35,975,908
Ensembl chr 2:35,764,686...35,975,872
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
decreases expression |
EXP |
Daunorubicin results in decreased expression of CXCR4 mRNA |
CTD |
PMID:27090888 |
|
NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883
|
|
G |
Cyba |
cytochrome b-245 alpha chain |
multiple interactions increases expression |
EXP |
telmisartan inhibits the reaction [Daunorubicin results in increased expression of CYBA protein] |
CTD |
PMID:21054405 |
|
NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721
|
|
G |
Cybb |
cytochrome b-245 beta chain |
increases expression |
EXP |
Daunorubicin results in increased expression of CYBB mRNA |
CTD |
PMID:27090888 |
|
NCBI chr X:13,360,583...13,392,517
Ensembl chr X:13,359,430...13,392,586
|
|
G |
Cycs |
cytochrome c, somatic |
affects expression |
ISO |
Daunorubicin affects the expression of CYCS mRNA |
CTD |
PMID:27780733 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
affects response to substance |
ISO |
CYP1B1 affects the susceptibility to Daunorubicin |
CTD |
PMID:18451141 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Dffa |
DNA fragmentation factor subunit alpha |
increases degradation |
ISO |
Daunorubicin results in increased degradation of DFFA protein |
CTD |
PMID:12370496 |
|
NCBI chr 5:159,540,718...159,553,639
Ensembl chr 5:159,540,715...159,553,633
|
|
G |
Dmd |
dystrophin |
decreases expression |
ISO |
Daunorubicin results in decreased expression of DMD mRNA |
CTD |
PMID:26537877 PMID:28940058 |
|
NCBI chr X:47,272,324...49,504,219
Ensembl chr X:47,272,331...49,504,207
|
|
G |
Dusp4 |
dual specificity phosphatase 4 |
increases expression |
ISO |
Daunorubicin results in increased expression of DUSP4 mRNA |
CTD |
PMID:26537877 PMID:28940058 |
|
NCBI chr16:57,376,659...57,398,161
Ensembl chr16:57,377,229...57,398,138
|
|
G |
E2f5 |
E2F transcription factor 5 |
increases expression |
ISO |
Daunorubicin results in increased expression of E2F5 mRNA |
CTD |
PMID:12656675 |
|
NCBI chr 2:86,997,331...87,012,901
Ensembl chr 2:86,997,332...87,012,990
|
|
G |
Edn1 |
endothelin 1 |
increases expression multiple interactions |
EXP |
Daunorubicin results in increased expression of EDN1 protein telmisartan inhibits the reaction [Daunorubicin results in increased expression of EDN1 protein] |
CTD |
PMID:20888384 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Ednra |
endothelin receptor type A |
increases expression multiple interactions |
EXP |
Daunorubicin results in increased expression of EDNRA protein telmisartan inhibits the reaction [Daunorubicin results in increased expression of EDNRA protein] |
CTD |
PMID:20888384 |
|
NCBI chr19:30,233,540...30,303,727
Ensembl chr19:30,233,571...30,297,049
|
|
G |
Ednrb |
endothelin receptor type B |
increases expression multiple interactions |
EXP |
Daunorubicin results in increased expression of EDNRB protein telmisartan promotes the reaction [Daunorubicin results in increased expression of EDNRB protein] |
CTD |
PMID:20888384 |
|
NCBI chr15:80,640,839...80,672,115
Ensembl chr15:80,643,043...80,672,115
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
Daunorubicin inhibits the reaction [EGF protein results in increased abundance of Diglycerides] |
CTD |
PMID:11082532 |
|
NCBI chr 2:218,219,408...218,302,370
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Ei24 |
EI24, autophagy associated transmembrane protein |
increases expression |
ISO |
Daunorubicin results in increased expression of EI24 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 8:36,494,289...36,510,653
Ensembl chr 8:36,494,289...36,510,571
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
increases phosphorylation multiple interactions |
ISO |
Daunorubicin results in increased phosphorylation of EIF4EBP1 protein Sirolimus inhibits the reaction [Daunorubicin results in increased phosphorylation of EIF4EBP1 protein] |
CTD |
PMID:21898527 |
|
NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
|
|
G |
Eng |
endoglin |
decreases expression |
EXP |
Daunorubicin results in decreased expression of ENG mRNA |
CTD |
PMID:27090888 |
|
NCBI chr 3:15,934,566...15,972,618
Ensembl chr 3:15,934,518...15,973,230
|
|
G |
Epm2aip1 |
EPM2A interacting protein 1 |
increases expression |
ISO |
Daunorubicin results in increased expression of EPM2AIP1 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 8:111,233,871...111,241,219
Ensembl chr 8:111,233,826...111,241,871
|
|
G |
Erbb3 |
erb-b2 receptor tyrosine kinase 3 |
decreases expression |
ISO |
Daunorubicin results in decreased expression of ERBB3 mRNA |
CTD |
PMID:26537877 PMID:28940058 |
|
NCBI chr 7:994,549...1,015,876
Ensembl chr 7:996,225...1,015,525
|
|
G |
Esr1 |
estrogen receptor 1 |
decreases activity increases activity |
ISO |
Daunorubicin results in decreased activity of ESR1 protein Daunorubicin results in increased activity of ESR1 protein |
CTD |
PMID:25257666 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
F3 |
coagulation factor III, tissue factor |
increases expression |
ISO |
Daunorubicin results in increased expression of F3 mRNA; Daunorubicin results in increased expression of F3 protein |
CTD |
PMID:11721405 |
|
NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668
|
|
G |
Fas |
Fas cell surface death receptor |
increases expression |
ISO |
Daunorubicin results in increased expression of FAS mRNA |
CTD |
PMID:26537877 PMID:28940058 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Faslg |
Fas ligand |
multiple interactions increases expression |
EXP |
candesartan inhibits the reaction [Daunorubicin results in increased expression of FASLG protein] |
CTD |
PMID:16324756 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fdxr |
ferredoxin reductase |
increases expression |
ISO |
Daunorubicin results in increased expression of FDXR mRNA |
CTD |
PMID:17374387 |
|
NCBI chr10:100,507,863...100,516,649
Ensembl chr10:100,507,865...100,516,658
|
|
G |
Gapt |
Grb2-binding adaptor protein, transmembrane |
affects response to substance |
ISO |
GAPT affects the susceptibility to Daunorubicin |
CTD |
PMID:17545624 |
|
NCBI chr 2:41,927,533...41,932,120
Ensembl chr 2:41,927,532...41,932,093
|
|
G |
Gdf15 |
growth differentiation factor 15 |
increases expression |
ISO |
Daunorubicin results in increased expression of GDF15 mRNA |
CTD |
PMID:26537877 PMID:28940058 |
|
NCBI chr16:18,805,312...18,807,893
Ensembl chr16:18,805,239...18,808,055
|
|
G |
Gpc5 |
glypican 5 |
affects response to substance |
ISO |
GPC5 affects the susceptibility to Daunorubicin |
CTD |
PMID:17545624 |
|
NCBI chr15:92,207,275...93,644,054
Ensembl chr15:92,239,176...93,643,282
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
increases expression |
ISO |
Daunorubicin results in increased expression of GPX1 mRNA |
CTD |
PMID:26537877 PMID:28940058 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
affects response to substance |
ISO |
GSTM1 gene polymorphism affects the susceptibility to Daunorubicin |
CTD |
PMID:15713801 |
|
NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411
|
|
G |
H2ax |
H2A.X variant histone |
affects expression increases expression |
ISO |
Daunorubicin affects the expression of H2AX mRNA Daunorubicin results in increased expression of H2AX protein |
CTD |
PMID:27780733 PMID:34963561 |
|
NCBI chr 8:44,671,927...44,673,257
Ensembl chr 8:44,671,786...44,673,239
|
|
G |
Hnrnpd |
heterogeneous nuclear ribonucleoprotein D |
affects response to substance |
ISO |
HNRNPD affects the susceptibility to Daunorubicin |
CTD |
PMID:18451141 |
|
NCBI chr14:9,615,375...9,638,975
Ensembl chr14:9,615,479...9,633,786
|
|
G |
Hrc |
histidine rich calcium binding protein |
decreases expression |
ISO |
Daunorubicin results in decreased expression of HRC mRNA |
CTD |
PMID:26537877 PMID:28940058 |
|
NCBI chr 1:95,813,262...95,816,987
Ensembl chr 1:95,813,253...95,816,984
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
increases expression multiple interactions |
EXP |
Daunorubicin results in increased expression of ICAM1 protein telmisartan inhibits the reaction [Daunorubicin results in increased expression of ICAM1 protein] |
CTD |
PMID:20888384 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Ikbke |
inhibitor of nuclear factor kappa B kinase subunit epsilon |
affects response to substance |
ISO |
IKBKE affects the susceptibility to Daunorubicin |
CTD |
PMID:18451141 |
|
NCBI chr13:42,712,154...42,738,470
Ensembl chr13:42,712,159...42,737,143
|
|
G |
Il6r |
interleukin 6 receptor |
decreases expression |
ISO |
Daunorubicin results in decreased expression of IL6R protein modified form |
CTD |
PMID:20116850 |
|
NCBI chr 2:175,289,157...175,347,719
Ensembl chr 2:175,298,686...175,347,536
|
|
G |
Ilkap |
ILK associated serine/threonine phosphatase |
affects response to substance |
ISO |
ILKAP affects the susceptibility to Daunorubicin |
CTD |
PMID:17545624 |
|
NCBI chr 9:91,966,440...91,988,791
Ensembl chr 9:91,966,441...91,988,892
|
|
G |
Inpp4b |
inositol polyphosphate-4-phosphatase type II B |
affects response to substance |
ISO |
INPP4B affects the susceptibility to Daunorubicin |
CTD |
PMID:17545624 |
|
NCBI chr19:25,920,189...26,670,085
Ensembl chr19:25,925,358...26,280,634
|
|
G |
Irx4 |
iroquois homeobox 4 |
decreases expression |
ISO |
Daunorubicin results in decreased expression of IRX4 mRNA |
CTD |
PMID:26537877 PMID:28940058 |
|
NCBI chr 1:30,030,561...30,039,549
Ensembl chr 1:30,030,561...30,039,549
|
|
G |
Jak2 |
Janus kinase 2 |
decreases expression |
ISO |
Daunorubicin results in decreased expression of JAK2 mRNA |
CTD |
PMID:26537877 PMID:28940058 |
|
NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases expression |
ISO |
Daunorubicin results in decreased expression of KCNH2 mRNA |
CTD |
PMID:26537877 PMID:28940058 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Kcnj2 |
potassium inwardly-rectifying channel, subfamily J, member 2 |
increases expression |
ISO |
Daunorubicin results in increased expression of KCNJ2 mRNA |
CTD |
PMID:26537877 PMID:28940058 |
|
NCBI chr10:96,060,849...96,071,401
Ensembl chr10:96,060,821...96,071,445
|
|
G |
Kcnq1 |
potassium voltage-gated channel subfamily Q member 1 |
decreases expression |
ISO |
Daunorubicin results in decreased expression of KCNQ1 mRNA |
CTD |
PMID:26537877 PMID:28940058 |
|
NCBI chr 1:198,291,711...198,624,683
Ensembl chr 1:198,291,766...198,624,669
|
|
G |
Kif1a |
kinesin family member 1A |
affects response to substance |
ISO |
KIF1A affects the susceptibility to Daunorubicin |
CTD |
PMID:17545624 |
|
NCBI chr 9:93,563,033...93,647,412
Ensembl chr 9:93,563,045...93,647,480
|
|
G |
Kit |
KIT proto-oncogene receptor tyrosine kinase |
decreases expression |
EXP |
Daunorubicin results in decreased expression of KIT mRNA |
CTD |
PMID:27090888 |
|
NCBI chr14:32,547,459...32,624,694
Ensembl chr14:32,548,877...32,624,652
|
|
G |
Kitlg |
KIT ligand |
decreases expression |
EXP |
Daunorubicin results in decreased expression of KITLG mRNA |
CTD |
PMID:27090888 |
|
NCBI chr 7:34,896,075...34,977,215
Ensembl chr 7:34,896,053...34,977,214
|
|
G |
Krt19 |
keratin 19 |
increases expression |
EXP |
Daunorubicin results in increased expression of KRT19 protein |
CTD |
PMID:2444108 |
|
NCBI chr10:85,075,835...85,080,552
Ensembl chr10:85,066,802...85,171,799
|
|
G |
Krt8 |
keratin 8 |
increases expression |
EXP |
Daunorubicin results in increased expression of KRT8 protein |
CTD |
PMID:2444108 |
|
NCBI chr 7:133,124,203...133,131,656
Ensembl chr 7:133,124,203...133,131,728
|
|
G |
Ldb3 |
LIM domain binding 3 |
decreases expression |
ISO |
Daunorubicin results in decreased expression of LDB3 mRNA |
CTD |
PMID:26537877 PMID:28940058 |
|
NCBI chr16:9,855,768...9,920,108
Ensembl chr16:9,855,927...9,918,532
|
|
G |
Lsamp |
limbic system-associated membrane protein |
affects response to substance |
ISO |
LSAMP affects the susceptibility to Daunorubicin |
CTD |
PMID:17545624 |
|
NCBI chr11:58,547,533...60,717,329
Ensembl chr11:58,554,805...60,717,029
|
|
G |
Luzp2 |
leucine zipper protein 2 |
affects response to substance |
ISO |
LUZP2 affects the susceptibility to Daunorubicin |
CTD |
PMID:17545624 |
|
NCBI chr 1:105,597,291...105,983,605
Ensembl chr 1:105,597,307...105,981,183
|
|
G |
Map1b |
microtubule-associated protein 1B |
affects response to substance |
ISO |
MAP1B affects the susceptibility to Daunorubicin |
CTD |
PMID:17545624 |
|
NCBI chr 2:30,817,261...30,910,458
Ensembl chr 2:30,817,261...30,910,317
|
|
G |
Map2k1 |
mitogen activated protein kinase kinase 1 |
multiple interactions |
ISO |
MAP2K1 protein inhibits the reaction [Daunorubicin results in decreased expression of SP1 protein]; MAP2K1 protein inhibits the reaction [Daunorubicin results in decreased phosphorylation of MAPK1 protein]; MAP2K1 protein inhibits the reaction [Daunorubicin results in decreased phosphorylation of MAPK3 protein]; MAP2K1 protein inhibits the reaction [Daunorubicin results in increased expression of BTRC mRNA]; MAP2K1 protein inhibits the reaction [Daunorubicin results in increased expression of BTRC protein] |
CTD |
PMID:34963561 |
|
NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147
|
|
G |
Map2k3 |
mitogen activated protein kinase kinase 3 |
increases expression |
ISO |
Daunorubicin results in increased expression of MAP2K3 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr10:45,608,145...45,629,492
Ensembl chr10:45,607,163...45,629,492
|
|
G |
Map3k5 |
mitogen-activated protein kinase kinase kinase 5 |
decreases expression |
ISO |
Daunorubicin results in decreased expression of MAP3K5 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 1:14,685,776...14,904,935
Ensembl chr 1:14,685,492...14,904,800
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions decreases phosphorylation |
ISO |
Acetylcysteine inhibits the reaction [Daunorubicin results in decreased phosphorylation of MAPK1 protein]; AKT1 protein inhibits the reaction [Daunorubicin results in decreased phosphorylation of MAPK1 protein]; MAP2K1 protein inhibits the reaction [Daunorubicin results in decreased phosphorylation of MAPK1 protein] |
CTD |
PMID:34963561 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions decreases phosphorylation |
ISO |
Acetylcysteine inhibits the reaction [Daunorubicin results in decreased phosphorylation of MAPK3 protein]; AKT1 protein inhibits the reaction [Daunorubicin results in decreased phosphorylation of MAPK3 protein]; MAP2K1 protein inhibits the reaction [Daunorubicin results in decreased phosphorylation of MAPK3 protein] |
CTD |
PMID:34963561 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapt |
microtubule-associated protein tau |
decreases expression |
ISO |
Daunorubicin results in decreased expression of MAPT mRNA; Daunorubicin results in decreased expression of MAPT protein |
CTD |
PMID:16930453 |
|
NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
decreases expression multiple interactions |
ISO |
Daunorubicin results in decreased expression of MCL1 mRNA; Daunorubicin results in decreased expression of MCL1 protein 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Daunorubicin results in decreased expression of MCL1 mRNA]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Daunorubicin results in decreased expression of MCL1 protein]; [4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole co-treated with AKT1 protein] inhibits the reaction [Daunorubicin results in decreased expression of MCL1 mRNA]; [4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole co-treated with AKT1 protein] inhibits the reaction [Daunorubicin results in decreased expression of MCL1 protein]; AKT1 protein inhibits the reaction [Daunorubicin results in decreased expression of MCL1 mRNA]; AKT1 protein inhibits the reaction [Daunorubicin results in decreased expression of MCL1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Daunorubicin results in decreased expression of MCL1 protein]; SP1 protein inhibits the reaction [Daunorubicin results in decreased expression of MCL1 protein] |
CTD |
PMID:34963561 |
|
NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
|
|
G |
Mdm4 |
MDM4 regulator of p53 |
decreases expression |
ISO |
Daunorubicin results in decreased expression of MDM4 mRNA |
CTD |
PMID:12656675 |
|
NCBI chr13:44,432,596...44,516,165
Ensembl chr13:44,406,213...44,474,226
|
|
G |
Mir21 |
microRNA 21 |
decreases response to substance |
ISO |
MIR21 results in decreased susceptibility to Daunorubicin |
CTD |
PMID:21187093 |
|
NCBI chr10:71,405,257...71,405,348
Ensembl chr10:71,405,257...71,405,348
|
|
G |
Mt1 |
metallothionein 1 |
increases expression multiple interactions |
EXP |
Daunorubicin results in increased expression of MT1A mRNA; Daunorubicin results in increased expression of MT1A protein Zinc promotes the reaction [Daunorubicin results in increased expression of MT1A mRNA]; Zinc promotes the reaction [Daunorubicin results in increased expression of MT1A protein] |
CTD |
PMID:12204545 |
|
NCBI chr19:10,826,032...10,827,048
Ensembl chr19:10,826,032...10,827,049
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
increases phosphorylation multiple interactions |
ISO |
Daunorubicin results in increased phosphorylation of MTOR protein Sirolimus inhibits the reaction [Daunorubicin results in increased phosphorylation of MTOR protein] |
CTD |
PMID:21898527 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Myh6 |
myosin heavy chain 6 |
decreases expression |
ISO EXP |
Daunorubicin results in decreased expression of MYH6 mRNA |
CTD |
PMID:26537877 PMID:27090888 PMID:28940058 |
|
NCBI chr15:28,418,120...28,442,316
Ensembl chr15:28,417,616...28,441,720
|
|
G |
Myh7 |
myosin heavy chain 7 |
increases expression decreases expression |
EXP ISO |
Daunorubicin results in increased expression of MYH7 mRNA Daunorubicin results in decreased expression of MYH7 mRNA |
CTD |
PMID:26328012 PMID:26537877 PMID:27090888 PMID:28940058 |
|
NCBI chr15:28,446,550...28,469,888
Ensembl chr15:28,446,550...28,468,217
|
|
G |
Myom2 |
myomesin 2 |
decreases expression |
ISO |
Daunorubicin results in decreased expression of MYOM2 mRNA |
CTD |
PMID:26537877 PMID:28940058 |
|
NCBI chr16:74,520,148...74,592,658
Ensembl chr16:74,520,157...74,592,772
|
|
G |
Ncf1 |
neutrophil cytosolic factor 1 |
multiple interactions increases expression |
EXP |
telmisartan inhibits the reaction [Daunorubicin results in increased expression of NCF1 protein] |
CTD |
PMID:21054405 |
|
NCBI chr12:22,485,382...22,494,647
Ensembl chr12:22,485,451...22,494,646
|
|
G |
Ncf2 |
neutrophil cytosolic factor 2 |
increases expression multiple interactions |
EXP |
Daunorubicin results in increased expression of NCF2 protein telmisartan inhibits the reaction [Daunorubicin results in increased expression of NCF2 protein] |
CTD |
PMID:21054405 |
|
NCBI chr13:64,955,502...64,986,289
Ensembl chr13:64,955,503...64,986,277
|
|
G |
Nck2 |
NCK adaptor protein 2 |
decreases expression |
ISO |
Daunorubicin results in decreased expression of NCK2 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 9:45,713,979...45,840,330
Ensembl chr 9:45,714,883...45,840,307
|
|
G |
Ncoa2 |
nuclear receptor coactivator 2 |
multiple interactions |
ISO |
Daunorubicin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein affects the localization of NCOA2 protein]] |
CTD |
PMID:25257666 |
|
NCBI chr 5:5,835,642...6,069,693
Ensembl chr 5:5,835,706...6,067,451
|
|
G |
Ngef |
neuronal guanine nucleotide exchange factor |
affects response to substance |
ISO |
NGEF affects the susceptibility to Daunorubicin |
CTD |
PMID:17545624 |
|
NCBI chr 9:88,146,956...88,244,454
Ensembl chr 9:88,146,956...88,244,914
|
|
G |
Nox4 |
NADPH oxidase 4 |
increases expression multiple interactions |
EXP ISO |
Daunorubicin results in increased expression of NOX4 protein telmisartan inhibits the reaction [Daunorubicin results in increased expression of NOX4 protein] Daunorubicin results in increased expression of NOX4 mRNA |
CTD |
PMID:21054405 PMID:34963561 |
|
NCBI chr 1:140,900,886...141,078,844
Ensembl chr 1:140,901,097...141,077,406
|
|
G |
Npc1 |
NPC intracellular cholesterol transporter 1 |
multiple interactions affects response to substance increases secretion |
ISO |
Nocodazole inhibits the reaction [NPC1 protein results in increased secretion of Daunorubicin]; Progesterone inhibits the reaction [NPC1 protein results in increased secretion of Daunorubicin] NPC1 affects the susceptibility to Daunorubicin |
CTD |
PMID:16174794 |
|
NCBI chr18:3,379,482...3,425,100
Ensembl chr18:3,379,482...3,425,049
|
|
G |
Nphs1 |
NPHS1 adhesion molecule, nephrin |
multiple interactions decreases expression |
EXP |
Telmisartan inhibits the reaction [Daunorubicin results in decreased expression of NPHS1 protein] |
CTD |
PMID:20888384 |
|
NCBI chr 1:85,720,812...85,749,079
Ensembl chr 1:85,720,812...85,749,078
|
|
G |
Nppa |
natriuretic peptide A |
increases expression |
EXP |
Daunorubicin results in increased expression of NPPA mRNA |
CTD |
PMID:26328012 PMID:27090888 |
|
NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Nppb |
natriuretic peptide B |
decreases expression increases expression |
EXP ISO |
Daunorubicin results in decreased expression of NPPB mRNA; Daunorubicin results in decreased expression of NPPB protein Daunorubicin results in increased expression of NPPB protein Daunorubicin results in increased expression of NPPB mRNA |
CTD |
PMID:11279304 PMID:17673002 PMID:26328012 PMID:27090888 |
|
NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases activity decreases expression |
EXP ISO |
Daunorubicin results in increased activity of NQO1 protein Daunorubicin results in decreased expression of NQO1 mRNA; Daunorubicin results in decreased expression of NQO1 protein |
CTD |
PMID:3986001 PMID:8875677 PMID:9620540 PMID:22021338 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions increases activity decreases activity |
ISO |
Daunorubicin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein affects the localization of NCOA2 protein]]; Daunorubicin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Daunorubicin inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein] Daunorubicin results in increased activity of NR1H4 protein Daunorubicin results in decreased activity of NR1H4 protein |
CTD |
PMID:25257666 |
|
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
decreases activity |
ISO |
Daunorubicin results in decreased activity of NR3C1 protein |
CTD |
PMID:19255438 |
|
NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375
|
|
G |
Nrap |
nebulin-related anchoring protein |
decreases expression |
ISO |
Daunorubicin results in decreased expression of NRAP mRNA |
CTD |
PMID:26537877 PMID:28940058 |
|
NCBI chr 1:255,350,113...255,427,704
Ensembl chr 1:255,350,113...255,427,693
|
|
G |
Nras |
NRAS proto-oncogene, GTPase |
increases expression |
ISO |
Daunorubicin results in increased expression of NRAS mRNA |
CTD |
PMID:12656675 |
|
NCBI chr 2:190,582,885...190,593,509
Ensembl chr 2:190,582,918...190,591,626
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases cleavage affects expression |
ISO |
[Daunorubicin co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein Daunorubicin results in increased cleavage of PARP1 protein Daunorubicin affects the expression of PARP1 mRNA |
CTD |
PMID:10766178 PMID:11082532 PMID:12780785 PMID:27780733 PMID:34963561 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pfkm |
phosphofructokinase, muscle |
decreases expression |
EXP |
Daunorubicin results in decreased expression of PFKM mRNA |
CTD |
PMID:9038198 |
|
NCBI chr 7:129,221,679...129,259,192
Ensembl chr 7:129,221,653...129,259,192
|
|
G |
Pik3r1 |
phosphoinositide-3-kinase regulatory subunit 1 |
affects response to substance |
ISO |
PIK3R1 affects the susceptibility to Daunorubicin |
CTD |
PMID:17545624 |
|
NCBI chr 2:32,878,942...32,963,611
Ensembl chr 2:32,882,032...32,963,631
|
|
G |
Plat |
plasminogen activator, tissue type |
multiple interactions |
ISO |
[Daunorubicin results in increased abundance of Ceramides] which results in increased secretion of PLAT protein |
CTD |
PMID:11107162 |
|
NCBI chr16:69,240,582...69,265,177
Ensembl chr16:69,240,585...69,268,223
|
|
G |
Plk3 |
polo-like kinase 3 |
increases expression |
ISO |
Daunorubicin results in increased expression of PLK3 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 5:130,607,142...130,612,317
Ensembl chr 5:130,607,142...130,612,317
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
increases expression |
EXP |
Daunorubicin results in increased expression of PPARA mRNA |
CTD |
PMID:23834779 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Ppard |
peroxisome proliferator-activated receptor delta |
multiple interactions decreases activity |
EXP ISO |
[Enalaprilat co-treated with Daunorubicin] results in increased expression of PPARD mRNA Daunorubicin results in decreased activity of PPARD protein |
CTD |
PMID:23834779 PMID:25257666 |
|
NCBI chr20:6,298,785...6,363,970
Ensembl chr20:6,298,785...6,363,968
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions increases expression decreases activity |
EXP ISO |
telmisartan promotes the reaction [Daunorubicin results in increased expression of PPARG protein] Daunorubicin results in decreased activity of PPARG protein |
CTD |
PMID:20888384 PMID:25257666 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppp1r13l |
protein phosphatase 1, regulatory subunit 13 like |
decreases response to substance |
ISO |
PPP1R13L results in decreased susceptibility to Daunorubicin |
CTD |
PMID:19299014 |
|
NCBI chr 1:79,010,997...79,030,714
Ensembl chr 1:79,011,745...79,030,712
|
|
G |
Ppp1r3a |
protein phosphatase 1, regulatory subunit 3A |
decreases expression |
ISO |
Daunorubicin results in decreased expression of PPP1R3A mRNA |
CTD |
PMID:26537877 PMID:28940058 |
|
NCBI chr 4:42,937,353...42,980,195
Ensembl chr 4:42,939,599...42,980,638
|
|
G |
Ppp2ca |
protein phosphatase 2 catalytic subunit alpha |
increases expression multiple interactions |
ISO |
Daunorubicin results in increased expression of PPP2CA protein 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Daunorubicin results in increased expression of PPP2CA protein] |
CTD |
PMID:34963561 |
|
NCBI chr10:36,358,110...36,377,864
Ensembl chr10:36,358,101...36,377,862
|
|
G |
Prc1 |
protein regulator of cytokinesis 1 |
decreases expression |
ISO |
Daunorubicin results in decreased expression of PRC1 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 1:134,250,086...134,271,765
Ensembl chr 1:134,250,081...134,271,765
|
|
G |
Prdm16 |
PR/SET domain 16 |
decreases expression |
ISO |
Daunorubicin results in decreased expression of PRDM16 mRNA |
CTD |
PMID:26537877 PMID:28940058 |
|
NCBI chr 5:164,879,864...165,203,986
Ensembl chr 5:164,880,587...165,203,601
|
|
G |
Prkcd |
protein kinase C, delta |
increases cleavage |
ISO |
Daunorubicin results in increased cleavage of PRKCD protein |
CTD |
PMID:11082532 |
|
NCBI chr16:5,769,226...5,807,214
Ensembl chr16:5,769,215...5,799,352
|
|
G |
Prkcz |
protein kinase C, zeta |
decreases response to substance |
ISO |
PRKCZ protein results in decreased susceptibility to Daunorubicin |
CTD |
PMID:21863889 |
|
NCBI chr 5:165,817,786...165,930,386
Ensembl chr 5:165,819,466...165,930,367
|
|
G |
Prkx |
protein kinase cAMP-dependent X-linked catalytic subunit |
increases expression |
ISO |
Daunorubicin results in increased expression of PRKX mRNA |
CTD |
PMID:26537877 PMID:28940058 |
|
NCBI chr X:41,823,349...41,866,844
Ensembl chr X:41,823,355...41,866,669
|
|
G |
Prom1 |
prominin 1 |
decreases expression |
EXP |
Daunorubicin results in decreased expression of PROM1 mRNA |
CTD |
PMID:27090888 |
|
NCBI chr14:66,989,545...67,094,534
Ensembl chr14:66,990,160...67,094,527
|
|
G |
Pten |
phosphatase and tensin homolog |
increases response to substance |
ISO |
PTEN results in increased susceptibility to Daunorubicin |
CTD |
PMID:21187093 |
|
NCBI chr 1:230,631,303...230,696,754
Ensembl chr 1:230,630,338...230,696,838
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression multiple interactions |
EXP |
Daunorubicin results in increased expression of PTGS2 protein telmisartan inhibits the reaction [Daunorubicin results in increased expression of PTGS2 protein] |
CTD |
PMID:20888384 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Pygm |
glycogen phosphorylase, muscle associated |
decreases expression |
ISO |
Daunorubicin results in decreased expression of PYGM mRNA |
CTD |
PMID:26537877 PMID:28940058 |
|
NCBI chr 1:203,690,550...203,705,369
Ensembl chr 1:203,690,533...203,705,368
|
|
G |
Ranbp17 |
RAN binding protein 17 |
affects response to substance |
ISO |
RANBP17 affects the susceptibility to Daunorubicin |
CTD |
PMID:17545624 |
|
NCBI chr10:17,800,406...18,102,947
Ensembl chr10:17,800,999...18,102,831
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
increases expression |
ISO |
Daunorubicin results in increased expression of RB1 mRNA |
CTD |
PMID:12656675 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Rbbp5 |
RB binding protein 5, histone lysine methyltransferase complex subunit |
affects expression |
ISO |
Daunorubicin affects the expression of RBBP5 mRNA |
CTD |
PMID:12656675 |
|
NCBI chr13:43,912,254...43,939,107
Ensembl chr13:43,912,254...43,939,107
|
|
G |
Rbbp6 |
RB binding protein 6, ubiquitin ligase |
increases expression |
ISO |
Daunorubicin results in increased expression of RBBP6 mRNA |
CTD |
PMID:12656675 |
|
NCBI chr 1:177,503,988...177,537,397
Ensembl chr 1:177,503,313...177,535,678
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
[Daunorubicin co-treated with Magnetite Nanoparticles] results in decreased expression of RELA protein |
CTD |
PMID:21518493 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rock1 |
Rho-associated coiled-coil containing protein kinase 1 |
affects expression multiple interactions |
EXP |
Daunorubicin affects the expression of ROCK1 mRNA fasudil affects the reaction [Daunorubicin affects the expression of ROCK1 mRNA] |
CTD |
PMID:20037814 |
|
NCBI chr18:1,114,532...1,236,345
Ensembl chr18:1,115,905...1,235,571
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
increases phosphorylation multiple interactions decreases expression |
ISO EXP |
Daunorubicin results in increased phosphorylation of RPS6KB1 protein Sirolimus inhibits the reaction [Daunorubicin results in increased phosphorylation of RPS6KB1 protein] Daunorubicin results in decreased expression of RPS6KB1 mRNA |
CTD |
PMID:21898527 PMID:28099878 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Ryr2 |
ryanodine receptor 2 |
multiple interactions decreases expression increases expression |
EXP ISO |
Razoxane inhibits the reaction [Daunorubicin results in decreased expression of RYR2 mRNA] Daunorubicin results in increased expression of RYR2 protein |
CTD |
PMID:10960060 PMID:26328012 PMID:26537877 PMID:28940058 |
|
NCBI chr17:58,389,925...58,975,641
Ensembl chr17:58,389,925...58,975,142
|
|
G |
Scn2b |
sodium voltage-gated channel beta subunit 2 |
decreases expression |
ISO |
Daunorubicin results in decreased expression of SCN2B mRNA |
CTD |
PMID:26537877 PMID:28940058 |
|
NCBI chr 8:45,425,629...45,437,765
Ensembl chr 8:45,425,629...45,437,765
|
|
G |
Scn5a |
sodium voltage-gated channel alpha subunit 5 |
decreases expression |
ISO |
Daunorubicin results in decreased expression of SCN5A mRNA |
CTD |
PMID:26537877 PMID:28940058 |
|
NCBI chr 8:119,220,905...119,318,816
Ensembl chr 8:119,220,905...119,318,769
|
|
G |
Sdc1 |
syndecan 1 |
increases expression |
ISO |
Daunorubicin results in increased expression of SDC1 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 6:31,562,799...31,585,267
Ensembl chr 6:31,562,739...31,585,264
|
|
G |
Serpine1 |
serpin family E member 1 |
decreases expression multiple interactions decreases secretion |
ISO EXP |
Daunorubicin results in decreased expression of SERPINE1 mRNA; Daunorubicin results in decreased expression of SERPINE1 protein [Daunorubicin results in increased abundance of Ceramides] which results in decreased secretion of SERPINE1 protein; fumonisin B1 inhibits the reaction [Daunorubicin results in decreased expression of SERPINE1 protein] Daunorubicin results in decreased secretion of SERPINE1 protein |
CTD |
PMID:11107162 PMID:11336794 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Slc22a16 |
solute carrier family 22 member 16 |
multiple interactions |
ISO |
Daunorubicin inhibits the reaction [SLC22A16 protein results in increased uptake of Doxorubicin] |
CTD |
PMID:15963465 |
|
NCBI chr20:43,972,808...44,068,447
Ensembl chr20:43,972,836...44,065,019
|
|
G |
Slc25a4 |
solute carrier family 25 member 4 |
decreases expression |
EXP |
Daunorubicin results in decreased expression of SLC25A4 mRNA |
CTD |
PMID:9038198 |
|
NCBI chr16:46,072,935...46,076,730
Ensembl chr16:46,072,939...46,076,733
|
|
G |
Slit3 |
slit guidance ligand 3 |
affects response to substance |
ISO |
SLIT3 affects the susceptibility to Daunorubicin |
CTD |
PMID:17545624 |
|
NCBI chr10:19,571,798...20,156,634
Ensembl chr10:19,571,684...20,156,634
|
|
G |
Smpd1 |
sphingomyelin phosphodiesterase 1 |
increases expression increases activity |
ISO |
Daunorubicin results in increased expression of SMPD1 mRNA Daunorubicin results in increased activity of SMPD1 protein |
CTD |
PMID:19698806 |
|
NCBI chr 1:159,892,946...159,896,789
Ensembl chr 1:159,892,859...159,896,794
|
|
G |
Smpd3 |
sphingomyelin phosphodiesterase 3 |
increases expression increases response to substance |
ISO |
Daunorubicin results in increased expression of SMPD3 mRNA; Daunorubicin results in increased expression of SMPD3 protein SMPD3 results in increased susceptibility to Daunorubicin |
CTD |
PMID:19698806 |
|
NCBI chr19:34,162,337...34,245,786
Ensembl chr19:34,162,341...34,245,749
|
|
G |
Sod2 |
superoxide dismutase 2 |
decreases secretion multiple interactions |
EXP |
Daunorubicin results in decreased secretion of SOD2 protein nebivolol inhibits the reaction [Daunorubicin results in decreased secretion of SOD2 protein] |
CTD |
PMID:18194856 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sp1 |
Sp1 transcription factor |
decreases expression multiple interactions |
ISO |
Daunorubicin results in decreased expression of SP1 protein AKT1 protein inhibits the reaction [Daunorubicin results in decreased expression of SP1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Daunorubicin results in decreased expression of SP1 protein]; BTRC protein inhibits the reaction [Daunorubicin results in decreased expression of SP1 protein]; BTRC protein modified form inhibits the reaction [Daunorubicin results in decreased expression of SP1 protein]; MAP2K1 protein inhibits the reaction [Daunorubicin results in decreased expression of SP1 protein]; SP1 protein inhibits the reaction [Daunorubicin results in decreased expression of MCL1 protein] |
CTD |
PMID:34963561 |
|
NCBI chr 7:133,541,302...133,571,961
Ensembl chr 7:133,541,491...133,571,961
|
|
G |
Sp110 |
SP110 nuclear body protein |
affects response to substance |
ISO |
SP110 affects the susceptibility to Daunorubicin |
CTD |
PMID:17545624 |
|
NCBI chr 9:86,200,503...86,225,355
Ensembl chr 9:86,200,503...86,222,670
|
|
G |
Sp3 |
Sp3 transcription factor |
increases expression |
ISO |
Daunorubicin results in increased expression of SP3 protein |
CTD |
PMID:19698806 |
|
NCBI chr 3:57,811,855...57,857,150
Ensembl chr 3:57,812,075...57,860,342
|
|
G |
Spmip2 |
sperm microtubule inner protein 2 |
affects response to substance |
ISO |
C4ORF45 affects the susceptibility to Daunorubicin |
CTD |
PMID:17545624 |
|
NCBI chr 2:164,490,211...164,604,379
Ensembl chr 2:164,490,252...164,604,379
|
|
G |
Tagln3 |
transgelin 3 |
affects response to substance |
ISO |
TAGLN3 affects the susceptibility to Daunorubicin |
CTD |
PMID:17545624 |
|
NCBI chr11:55,099,887...55,113,457
Ensembl chr11:55,099,743...55,113,485
|
|
G |
Tap1 |
transporter 1, ATP binding cassette subfamily B member |
increases expression |
ISO |
Daunorubicin results in increased expression of TAP1 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr20:4,656,262...4,666,634
Ensembl chr20:4,656,263...4,666,901
|
|
G |
Tap2 |
transporter 2, ATP binding cassette subfamily B member |
affects response to substance |
ISO |
TAP2 affects the susceptibility to Daunorubicin |
CTD |
PMID:18451141 |
|
NCBI chr20:4,636,347...4,650,387
Ensembl chr20:4,636,357...4,650,407
|
|
G |
Tax1bp3 |
Tax1 binding protein 3 |
increases expression |
ISO |
Daunorubicin results in increased expression of TAX1BP3 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr10:57,795,785...57,800,363
Ensembl chr10:57,795,382...57,800,363
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions increases expression |
EXP |
telmisartan inhibits the reaction [Daunorubicin results in increased expression of TGFB1 protein] |
CTD |
PMID:20888384 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tlr4 |
toll-like receptor 4 |
decreases response to substance |
ISO |
TLR4 protein results in decreased susceptibility to Daunorubicin |
CTD |
PMID:18789402 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tm4sf20 |
transmembrane 4 L six family member 20 |
affects response to substance |
ISO |
TM4SF20 affects the susceptibility to Daunorubicin |
CTD |
PMID:17545624 |
|
NCBI chr 9:84,038,715...84,052,615
Ensembl chr 9:84,038,715...84,052,615
|
|
G |
Tnf |
tumor necrosis factor |
increases expression |
EXP |
Daunorubicin results in increased expression of TNF protein |
CTD |
PMID:16626513 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf10b |
TNF receptor superfamily member 10b |
multiple interactions |
ISO |
Daunorubicin promotes the reaction [TNFSF10 results in increased expression of TNFRSF10A mRNA] |
CTD |
PMID:17204177 |
|
NCBI chr15:44,839,818...44,867,582
Ensembl chr15:44,840,386...44,867,467
|
|
G |
Tnfsf10 |
TNF superfamily member 10 |
multiple interactions |
ISO |
[Daunorubicin co-treated with TNFSF10 protein] results in increased activity of CASP3 protein; [Daunorubicin co-treated with TNFSF10 protein] results in increased activity of CASP8 protein; [Daunorubicin co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein; [Daunorubicin co-treated with TNFSF10 protein] results in increased expression of BID protein; Daunorubicin promotes the reaction [TNFSF10 results in increased expression of TNFRSF10A mRNA]; Daunorubicin promotes the reaction [TNFSF10 results in increased expression of TNFRSF10B mRNA] |
CTD |
PMID:12780785 PMID:17204177 |
|
NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135
|
|
G |
Tnfsf9 |
TNF superfamily member 9 |
increases expression |
ISO |
Daunorubicin results in increased expression of TNFSF9 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 9:1,944,017...1,946,351
Ensembl chr 9:1,944,017...1,946,345
|
|
G |
Tnnt1 |
troponin T1, slow skeletal type |
decreases expression |
ISO |
Daunorubicin results in decreased expression of TNNT1 mRNA |
CTD |
PMID:26537877 PMID:28940058 |
|
NCBI chr 1:69,306,362...69,316,721
Ensembl chr 1:69,306,362...69,316,721
|
|
G |
Tnnt2 |
troponin T2, cardiac type |
multiple interactions increases secretion |
EXP |
nebivolol inhibits the reaction [Daunorubicin results in increased expression of TNNT2 protein] Daunorubicin results in increased secretion of TNNT2 protein |
CTD |
PMID:18194856 |
|
NCBI chr13:47,267,325...47,285,390
Ensembl chr13:47,267,204...47,285,388
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions increases expression increases activity affects activity |
ISO |
[Daunorubicin co-treated with Magnetite Nanoparticles] results in increased activity of TP53 protein; Daunorubicin results in increased phosphorylation of and results in increased expression of TP53 protein Daunorubicin results in increased expression of TP53 mRNA Daunorubicin results in increased activity of TP53 protein Daunorubicin affects the activity of TP53 protein |
CTD |
PMID:12112851 PMID:12656675 PMID:21518493 PMID:23872705 PMID:35435491 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tp53i3 |
tumor protein p53 inducible protein 3 |
increases expression |
ISO |
Daunorubicin results in increased expression of TP53I3 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 6:27,818,327...27,827,030
|
|
G |
Tyms |
thymidylate synthetase |
affects response to substance |
ISO |
TYMS gene polymorphism affects the susceptibility to Daunorubicin |
CTD |
PMID:15713801 |
|
NCBI chr 9:113,313,454...113,329,551
Ensembl chr 9:113,313,452...113,329,536
|
|
G |
Uqcrfs1 |
ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1 |
decreases expression |
EXP |
Daunorubicin results in decreased expression of UQCRFS1 mRNA |
CTD |
PMID:9038198 |
|
NCBI chr17:33,977,908...33,982,478
Ensembl chr17:33,977,921...33,982,479
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
increases expression multiple interactions |
EXP |
Daunorubicin results in increased expression of VCAM1 protein telmisartan inhibits the reaction [Daunorubicin results in increased expression of VCAM1 protein] |
CTD |
PMID:20888384 |
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|
G |
Vdr |
vitamin D receptor |
affects response to substance decreases activity |
ISO |
VDR gene polymorphism affects the susceptibility to Daunorubicin Daunorubicin results in decreased activity of VDR protein |
CTD |
PMID:15713801 PMID:25257666 |
|
NCBI chr 7:128,987,981...129,037,677
Ensembl chr 7:128,987,981...129,037,677
|
|
G |
Vegfa |
vascular endothelial growth factor A |
decreases expression |
ISO EXP |
Daunorubicin results in decreased expression of VEGFA protein Daunorubicin results in decreased expression of VEGFA mRNA |
CTD |
PMID:20116850 PMID:27090888 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vim |
vimentin |
increases expression |
EXP |
Daunorubicin results in increased expression of VIM protein |
CTD |
PMID:2444108 |
|
NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
|
|
G |
Zbtb20 |
zinc finger and BTB domain containing 20 |
affects response to substance |
ISO |
ZBTB20 affects the susceptibility to Daunorubicin |
CTD |
PMID:17545624 |
|
NCBI chr11:57,052,129...57,823,679
Ensembl chr11:57,072,880...57,510,210
|
|
G |
Zmat3 |
zinc finger, matrin type 3 |
increases expression |
ISO |
Daunorubicin results in increased expression of ZMAT3 mRNA |
CTD |
PMID:26537877 PMID:28940058 |
|
NCBI chr 2:115,106,050...115,136,863
Ensembl chr 2:115,106,966...115,136,863
|
|